Flowonix Now Can Market Prometra II Pump in U.S. for Use with Intrathecal Baclofen

Flowonix Now Can Market Prometra II Pump in U.S. for Use with Intrathecal Baclofen
0
(0)

The U.S. Food and Drug Administration (FDA) has given medical device company Flowonix approval to market the Prometra II Programmable Pump System for use with intrathecal baclofen to treat severe spasticity in diseases, including cerebral palsy (CP).

The device was introduced to the U.S. market in November. By extending its use to treat spasticity — the continuous contraction of certain muscles — the agency’s approval should markedly expand Prometra’s market. The muscle relaxant intrathecal baclofen — sold as Gablofen by PiramalLioresal by Saol Therapeutics, and also in generic formulations — is used for spasticity, a condition that affects most children with CP.

In the Flowonix Prometra system, medication is delivered directly into fluid surrounding the spinal canal (intrathecal space), rapidly reaching the brain and spinal cord. Because the pump is implanted under the skin, therapy dosing can be managed better than when using oral treatments.

“Over the last several years, physicians utilizing implantable pumps to deliver long-term baclofen infusions have only had one device option,” Charles Argoff, MD, an Albany Medical Center neurologist, said in a press release. “The availability of a totally new pump to assist in the management of severe spasticity allows for a meaningful new option for those patients who suffer from this condition.”

Approved for use in the U.S. in 2012 to deliver infumorph for pain management, the new-generation Prometra II pump uses an innovative pressure-driven, valve-gated system to deliver medication. The mechanism offers swift and broad-based spinal cord coverage, and enables a unique programming mode of intermittent flow followed by periods of no flow. In addition, a 10-year battery life will greatly reduce the number of surgical procedures patients will need for pump replacement.

“This is a major milestone for Flowonix,” said Larry Heaton, the company’s president and CEO. “We believe the community of clinicians treating severe spasticity with intrathecal baclofen will find the Prometra system to be a welcome addition to their [resources] for treating their patients, and we will be working with leading physicians in the field to establish Prometra as the standard of care in intrathecal baclofen therapy,” he said.

According to the American Association of Neurological Surgeons, roughly 12 million individuals worldwide are affected by spasticity. In cerebral palsy, symptom management can be complex and multifaceted, and can include electrical stimulation, botulinum toxin (Botox) injections, and occupational therapy.

The Prometra II pump has been implanted in more than 8,000 patients globally. It was approved in 2011 to treat severe spasticity in the United Kingdom and the European Union.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 70
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • ride-on toy vehicles
  • Prometra II
  • CP muscle tone, nutritional status
  • ride-on toy vehicles

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?